Amarin posts an­oth­er round of promis­ing car­dio out­comes da­ta for Vas­cepa. Cue more M&A chat­ter and ar­gu­ment

Build­ing on their first sur­pris­ing round of pos­i­tive car­dio re­sults for their in­dus­tri­al strength fish oil Vas­cepa, Amarin to­day out­lined a fresh set of da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER